Henderson Edward, Huynh Gabriel, Wilson Kirsty, Plebanski Magdalena, Corrie Simon
Department of Chemical and Biological Engineering, Monash University, Clayton, VIC 3800, Australia.
School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia.
Biomedicines. 2021 Oct 28;9(11):1554. doi: 10.3390/biomedicines9111554.
Ovarian cancer remains as one of the most lethal gynecological cancers to date, with major challenges associated with screening, diagnosis and treatment of the disease and an urgent need for new technologies that can meet these challenges. Nanomaterials provide new opportunities in diagnosis and therapeutic management of many different types of cancers. In this review, we highlight recent promising developments of nanoparticles designed specifically for the detection or imaging of ovarian cancer that have reached the preclinical stage of development. This includes contrast agents, molecular imaging agents and intraoperative aids that have been designed for integration into standard imaging procedures. While numerous nanoparticle systems have been developed for ovarian cancer detection and imaging, specific design criteria governing nanomaterial targeting, biodistribution and clearance from the peritoneal cavity remain key challenges that need to be overcome before these promising tools can accomplish significant breakthroughs into the clinical setting.
卵巢癌至今仍是最致命的妇科癌症之一，在该疾病的筛查、诊断和治疗方面存在重大挑战，迫切需要能够应对这些挑战的新技术。纳米材料为多种不同类型癌症的诊断和治疗管理提供了新机遇。在本综述中，我们重点介绍了专门设计用于卵巢癌检测或成像且已进入临床前开发阶段的纳米颗粒的近期有前景的进展。这包括已设计用于融入标准成像程序的造影剂、分子成像剂和术中辅助工具。虽然已经开发了许多用于卵巢癌检测和成像的纳米颗粒系统，但在这些有前景的工具能够在临床环境中取得重大突破之前，控制纳米材料靶向、生物分布和从腹腔清除的特定设计标准仍然是需要克服的关键挑战。
